Cytosorbents Corporation (CTSO) — Financial statements
Income statement, balance sheet, and cash flow for Cytosorbents Corporation — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 37↑4.1% | 36↑14.5% | 31↓10.4% | 35↓13.5% | 40 | |
| Cost of Revenue | 11↑1.0% | 10↑14.6% | 9↓34.6% | 14↑26.3% | 11 | |
| Gross Profit | 26↑5.4% | 25↑14.5% | 22↑5.9% | 21↓28.7% | 29 | |
| Operating Expenses | ||||||
| R&D Expenses | 5↓26.5% | 7↓55.6% | 16↑3.1% | 15↓7.7% | 16 | |
| General & Administrative Expenses | 0.00 | 0.00↓100.0% | 38↑1612.2% | 2↓94.3% | 38 | |
| Selling & Marketing Expenses | 0.00 | 0.00↓100.0% | 0.44↓25.2% | 0.58 | 0.00 | |
| SG&A Expenses | 36 | 0.00↓100.0% | 38↑1271.1% | 3↓92.7% | 38 | |
| Other Expenses | 0.00↓100.0% | 35 | 0.00↓100.0% | 34↑1223.4% | -3 | |
| Operating Expenses | 41↓2.8% | 42↓22.2% | 54↑3.2% | 52↑0.9% | 52 | |
| Total Costs & Expenses | 51↓2.1% | 52↓16.9% | 63↓4.8% | 66↑5.3% | 63 | |
| Operating Results | ||||||
| Operating Income | -14↑15.2% | -17↑47.5% | -32↓1.4% | -32↓38.6% | -23 | |
| Depreciation & Amortization | 2↑3.9% | 2↓22.4% | 2↑129.3% | 0.88↓21.9% | 1 | |
| EBITDA | -13↑17.1% | -15↑45.4% | -28↑7.1% | -30↓38.8% | -22 | |
| EBIT | -14↑15.2% | -17↑43.9% | -30↑3.2% | -31↓35.8% | -23 | |
| Interest & Other Income | ||||||
| Net Interest Income | -3↓86.7% | -1↓786.1% | -0.16↓219.1% | 0.13↑373.4% | 0.03 | |
| Interest Income | 0.00 | 0.00 | 0.00↓100.0% | 0.13↑375.0% | 0.03 | |
| Interest Expense | 3↑86.7% | 1↑786.1% | 0.16 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00↑100.0% | -2↓221.7% | -0.64 | 0.00 | |
| Other Income / Expenses | 6↑200.3% | -6↓397.9% | 2↑179.2% | -2↑6.5% | -3 | |
| Income Before Tax | -9↑61.6% | -22↑25.5% | -30↑11.3% | -34↓34.0% | -25 | |
| Income Tax Expense | -0.40↑76.3% | -2↓107.8% | -0.81↑25.5% | -1↓48.4% | -0.74 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -8↑60.4% | -21↑29.2% | -29↑10.9% | -33↓33.6% | -25 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -8↑60.4% | -21↑29.2% | -29↑10.9% | -33↓33.6% | -25 | |
| Bottom-Line Net Income | -8↑60.4% | -21↑29.2% | -29↑10.9% | -33↓33.6% | -25 | |
| EPS (Basic) | -0.13↑65.8% | -0.38↑41.5% | -0.65↑13.3% | -0.75↓31.6% | -0.57 | |
| EPS (Diluted) | -0.13↑65.8% | -0.38↑41.5% | -0.65↑13.3% | -0.75↓31.6% | -0.57 | |
| Weighted Average Shares | 62↑14.3% | 54↑21.9% | 45↑2.5% | 44↑0.5% | 43 | |
| Weighted Average Diluted Shares | 62↑14.3% | 54↑21.9% | 45↑2.5% | 44↑0.5% | 43 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.